A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Completed · Phase 1/Phase 2

Conditions studied: Non-Small Cell Lung Cancer (NSCLC)

In brief

This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study of PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid tumors. The study is to be conducted in two parts: the Dose Escalation Phase of PT-112 within the combination and the Dose Confirmation Phase in patients with non-small cell lung cancer who will be treated at the RP2D.

Key facts

Study ID

NCT03409458

Run by

Promontory Therapeutics Inc.

People needed

68

Starts

2018-04-24

Expected to finish

2022-08-31

Last updated by the study team

2023-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona — Phoenix, Arizona, United States
• Colorado — Aurora, Colorado, United States
• Florida — Jacksonville, Florida, United States
• Minnesota — Rochester, Minnesota, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Lausanne — Lausanne, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.